701.00GBp+0.43%Mkt Cap: 47.67M GBpP/E: —Last update: 2026-06-01
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 ther…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap47.67M GBp
Enterprise Value42.53M GBp
Revenue (TTM)—
Gross Profit-929.89K GBp
Net Income (TTM)-9.76M GBp
Revenue/Share—
Last Price701.00 GBp
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-6.27
EV/Revenue—
P/S—
P/B-64.04
EPS (TTM)-1.71
EPS (Forward)—
52W Range
124.0034% of range1800.00
52W High1800.00 GBp
52W Low124.00 GBp
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-816.50%
ROA-233.73%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.45M GBp
CapEx (TTM)3.92K GBp
FCF Margin—
FCF Yield-6.99%
Net Debt417.82K GBp
Net Debt/EBITDA-0.06
Balance Sheet
Debt/Equity1.68
Current Ratio1.38
Quick Ratio1.09
Book Value/Sh-0.1090 GBp
Cash/Share0.2630 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:400
Split DateDec 13, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.6.80M
Float4.83M
Insiders29.43%
Institutions0.60%
Technical
SMA 50810.26 (-13.5%)
SMA 200839.12 (-16.5%)
Beta1.43
S&P 52W Chg27.94%
Avg Vol (30d)25.82K
Avg Vol (10d)13.85K
Technical Indicators
RSI (14)43.8
MACD-31.4531
MACD Signal-45.3747
MACD Hist.+13.9216
BB Upper718.02 GBp
BB Middle680.50 GBp
BB Lower642.98 GBp
BB Width11.03%
ATR (14)61.39 GBp
Vol Ratio (20d)1.08x